Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | AMD1 | P17707 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929097 | 1.00 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15930980 | 0.91 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL16489873 | 0.91 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15723511 | 0.86 | ADORA2A (0.47) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15305461 | 0.85 | PRMT5 (0.57) | ADORA2AADORA2BAHCYPRMT5WDR77 | |
| SCHEMBL18858889 | 0.82 | AHCY (0.41) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946103 | 0.81 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14928579 | 0.81 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL20010218 | 0.80 | ADORA2A (0.45) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15746179 | 0.80 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9675668-B2 | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 | MODERNA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-09 | — | — | US | disclosed |
| US-9254311-B2 | Modified polynucleotides for the production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-8664194-B2 | Method for producing a protein of interest in a primate | MODERNA THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130259923-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259924-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130253043-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF G-CSF | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130245105-A1 | DLIN-KC2-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245106-A1 | METHOD OF PRODUCING A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | PHAX, IGF2BP1, NSUN2 | ADORA2A 1770/4885ADORA2B 2023/4885AHCY 2906/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ADORA2A 351/4885ADORA2B 410/4885AHCY 398/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ADORA2A 85/4885ADORA2B 141/4885AHCY 196/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | ADORA2A 2618/4885ADORA2B 2716/4885AHCY 4127/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ADORA2A 399/4885ADORA2B 409/4885AHCY 722/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | ADORA2A 105/4885ADORA2B 130/4885AHCY 862/4885 |
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | ADORA2A 3570/4885ADORA2B 3596/4885AHCY 4213/4885 |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | ADORA2A 2618/4885ADORA2B 2716/4885AHCY 4127/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | ADORA2A 3142/4885ADORA2B 3119/4885AHCY 2138/4885 |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | IGF2BP1, PAIP1, PHAX | ADORA2A 2069/4885ADORA2B 2858/4885AHCY 1934/4885 |
| US-20130245106-A1 | METHOD OF PRODUCING A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | ADORA2A 2972/4885ADORA2B 3546/4885AHCY 2486/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | ADORA2A 2541/4885ADORA2B 3123/4885AHCY 1321/4885 |
| US-20130245105-A1 | DLIN-KC2-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | KPNA2, NSUN2, PHAX | ADORA2A 2975/4885ADORA2B 3223/4885AHCY 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.